Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib Combinations in First-Line KRAS G12C-Mutated Advanced NSCLC
jRCT2051240292Phase 2Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of divarasib in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Percentage of Participants with Adverse Events. Started Oct 2025; status: recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240292.